1. Home
  2. DHC vs OMER Comparison

DHC vs OMER Comparison

Compare DHC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHC
  • OMER
  • Stock Information
  • Founded
  • DHC 1998
  • OMER 1994
  • Country
  • DHC United States
  • OMER United States
  • Employees
  • DHC N/A
  • OMER N/A
  • Industry
  • DHC Real Estate Investment Trusts
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • DHC Real Estate
  • OMER Health Care
  • Exchange
  • DHC Nasdaq
  • OMER Nasdaq
  • Market Cap
  • DHC 629.7M
  • OMER 530.2M
  • IPO Year
  • DHC N/A
  • OMER 2009
  • Fundamental
  • Price
  • DHC $2.63
  • OMER $9.21
  • Analyst Decision
  • DHC Hold
  • OMER Buy
  • Analyst Count
  • DHC 3
  • OMER 4
  • Target Price
  • DHC $4.50
  • OMER $22.50
  • AVG Volume (30 Days)
  • DHC 989.6K
  • OMER 509.4K
  • Earning Date
  • DHC 02-25-2025
  • OMER 03-31-2025
  • Dividend Yield
  • DHC 1.54%
  • OMER N/A
  • EPS Growth
  • DHC N/A
  • OMER N/A
  • EPS
  • DHC N/A
  • OMER N/A
  • Revenue
  • DHC $1,477,343,000.00
  • OMER N/A
  • Revenue This Year
  • DHC N/A
  • OMER N/A
  • Revenue Next Year
  • DHC $4.46
  • OMER N/A
  • P/E Ratio
  • DHC N/A
  • OMER N/A
  • Revenue Growth
  • DHC 6.62
  • OMER N/A
  • 52 Week Low
  • DHC $2.01
  • OMER $2.61
  • 52 Week High
  • DHC $4.24
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • DHC 69.67
  • OMER 49.57
  • Support Level
  • DHC $2.39
  • OMER $8.28
  • Resistance Level
  • DHC $2.50
  • OMER $9.08
  • Average True Range (ATR)
  • DHC 0.13
  • OMER 0.55
  • MACD
  • DHC 0.07
  • OMER -0.02
  • Stochastic Oscillator
  • DHC 97.08
  • OMER 56.45

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: